Results of a study comparing two rituximab based chemoimmunotherapy combinations for first line treatment of activated B-cell DLBCL.
Home / Resource Library / DA-REPOCH Versus R-CHOP for the Treatment of Activated B-Cell Subtype Diffuse Large B-Cell Lymphoma: A Community Center Experience